Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Addition of Prednisolone and Heparin in Patients Undergoing Controlled Ovarian Hyperstimulation (COH) for In Vitro Fertilization (IVF) With Failed IVF Cycles

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by National and Kapodistrian University of Athens
Information provided by (Responsible Party):
Siristatidis Charalampos, MD, PhD, National and Kapodistrian University of Athens Identifier:
First received: April 30, 2012
Last updated: November 29, 2013
Last verified: November 2013

The addition of heparin and prednisolone increases pregnancy outcome parameters in women undergoing In Vitro Fertilisation (IVF) with failed IVF cycles.

Condition Intervention Phase
Drug: Prednisolone and Heparin during COH for IVF
Drug: COH for IVF
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by National and Kapodistrian University of Athens:

Primary Outcome Measures:
  • live birth rate [ Time Frame: birth of a fetus alive ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • clinical pregnancy rate [ Time Frame: finding of a fetal heart at >6 gestational weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: January 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prednisolone and Heparin during COH for IVF Drug: Prednisolone and Heparin during COH for IVF
Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
Active Comparator: COH for IVF Drug: COH for IVF
Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.


Ages Eligible for Study:   25 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • personal history of ≥2 failed IVF/ICSI cycles
  • age <45 years
  • availability of fresh ejaculate sperm for IVF/ICSI procedures
  • confirmation of normal uterine cavity
  • presence of good quality (Grade I or II) embryos for transfer

Exclusion Criteria:

  • endocrine disorders
  • immune disorders
  • coagulation disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01590173

Contact: Charalampos Siristatidis, MD, PhD

3rd Department of Obstetrics & Gynecology Recruiting
Athens, Chaidari, Attica, Greece, 12642
Contact: Dimitrios Kassanos, Professor   
Contact: Charalampos , Chrelias    210 5832286 ext 0030      
Sub-Investigator: Dimitrios Kassanos, Professor         
Sub-Investigator: Charalampos Chrelias, MD, PhD         
Sponsors and Collaborators
National and Kapodistrian University of Athens
  More Information

Responsible Party: Siristatidis Charalampos, MD, PhD, Senior Lecturer, Director of the IVF Unit, National and Kapodistrian University of Athens Identifier: NCT01590173     History of Changes
Other Study ID Numbers: 123123
Study First Received: April 30, 2012
Last Updated: November 29, 2013
Health Authority: Greece: National Organization of Medicines

Keywords provided by National and Kapodistrian University of Athens:
Low molecular weight heparin
Recurrent implantation failure
Pregnancy rate

Additional relevant MeSH terms:
Genital Diseases, Female
Genital Diseases, Male
Calcium heparin
Heparin, Low-Molecular-Weight
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Gastrointestinal Agents
Hematologic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on February 25, 2015